Teva Pharmaceuticals USA Inc. has completed the purchase of three buildings on Brandywine Parkway in West Chester, which, together with three other buildings Teva owns in the same corporate park, firmly establishes a North America Research & Development campus focused primarily on biologics.
Teva purchased 400, 500 and 600 Brandywine Parkway, which the company had been leasing since 2007 and, along with 100, 200 and 300 Brandywine Parkway, now owns approximately 314,000 square feet in West Chester dedicated to feeding Teva’s future pipeline and portfolio.
Representing a significant investment over the last 12 years in capital improvements, infrastructure and now the purchase of these three buildings, Teva’s West Chester R&D campus houses clinical development and manufacturing processes for highly complex biologic medicines developed by Teva. The campus also includes laboratories where advanced preclinical and clinical testing is conducted to ensure the safety and effectiveness of new drugs. Approximately 650 employees will be based at Teva in West Chester by the end of 2019, including teams involved in combination product and device R&D, regulatory affairs, medical affairs, and support functions.
Teva employs approximately 7,000 employees in multiple locations in the US in manufacturing, commercial, R&D and administrative functions.